Penumbra, Inc. $PEN Shares Purchased by SG Americas Securities LLC

SG Americas Securities LLC boosted its holdings in Penumbra, Inc. (NYSE:PEN) by 818.3% during the first quarter, HoldingsChannel.com reports. The fund owned 102,035 shares of the company’s stock after acquiring an additional 90,924 shares during the period. SG Americas Securities LLC’s holdings in Penumbra were worth $33,505,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Larson Financial Group LLC lifted its holdings in shares of Penumbra by 4,100.0% in the 4th quarter. Larson Financial Group LLC now owns 84 shares of the company’s stock worth $26,000 after purchasing an additional 82 shares during the last quarter. CIBC Private Wealth Group LLC grew its stake in Penumbra by 2,700.0% during the 4th quarter. CIBC Private Wealth Group LLC now owns 84 shares of the company’s stock worth $26,000 after buying an additional 81 shares during the last quarter. Motiv8 Investments LLC acquired a new stake in Penumbra in the fourth quarter worth $27,000. Morse Asset Management Inc acquired a new stake in Penumbra in the fourth quarter worth $39,000. Finally, Farther Finance Advisors LLC lifted its stake in Penumbra by 27.1% in the fourth quarter. Farther Finance Advisors LLC now owns 178 shares of the company’s stock valued at $55,000 after buying an additional 38 shares during the last quarter. 88.88% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Penumbra news, Director Harpreet Grewal sold 100 shares of the company’s stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $328.22, for a total value of $32,822.00. Following the completion of the sale, the director directly owned 8,719 shares of the company’s stock, valued at approximately $2,861,750.18. This represents a 1.13% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 2.90% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on PEN shares. Royal Bank Of Canada reissued a “sector perform” rating and set a $374.00 target price on shares of Penumbra in a research note on Thursday, June 11th. Wall Street Zen upgraded shares of Penumbra to a “hold” rating in a research note on Saturday, May 9th. UBS Group reaffirmed a “neutral” rating and set a $374.00 price target on shares of Penumbra in a report on Thursday, February 26th. Citigroup reduced their price objective on Penumbra from $374.00 to $350.00 and set a “neutral” rating for the company in a research report on Thursday, May 7th. Finally, Evercore reissued an “outperform” rating and issued a $335.00 price objective on shares of Penumbra in a report on Thursday, May 7th. Three equities research analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $361.33.

Penumbra Stock Up 0.6%

Shares of PEN stock opened at $318.08 on Wednesday. Penumbra, Inc. has a 1 year low of $221.26 and a 1 year high of $362.41. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.95 and a current ratio of 6.02. The business’s fifty day moving average is $323.89 and its 200-day moving average is $328.75. The stock has a market cap of $12.51 billion, a PE ratio of 73.29, a price-to-earnings-growth ratio of 1.94 and a beta of 0.71.

Penumbra (NYSE:PEN) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.82 earnings per share for the quarter, missing the consensus estimate of $1.06 by ($0.24). Penumbra had a net margin of 11.76% and a return on equity of 10.87%. The firm had revenue of $374.76 million during the quarter, compared to analyst estimates of $370.47 million. During the same quarter last year, the company earned $0.83 EPS. The company’s quarterly revenue was up 15.6% compared to the same quarter last year. Equities analysts expect that Penumbra, Inc. will post 5.08 earnings per share for the current fiscal year.

Penumbra Profile

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.